Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab in Caucasian patients with polypoidal choroidal vasculopathy
2024-515640-22-00Phase 4Authorised
- Sponsor
- AIBILI
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of faricimab in polypoidal choroidal vasculopathy (PCV), sponsored by AIBILI. Primary endpoint: Change from baseline in BCVA at Weeks 40, 44, or 48. Planned start Aug 2025; status: authorised.
02
Drugs
faricimab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on 2024-515640-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515640-22-00.